{"name":"Archimedes Development Ltd","slug":"archimedes-development-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Pain","slug":"pain","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Immediate release morphine sulphate","genericName":"Immediate release morphine sulphate","slug":"immediate-release-morphine-sulphate","indication":"Acute pain management","status":"phase_3"}]}],"pipeline":[{"name":"Immediate release morphine sulphate","genericName":"Immediate release morphine sulphate","slug":"immediate-release-morphine-sulphate","phase":"phase_3","mechanism":"Morphine sulphate binds to opioid receptors in the central and peripheral nervous system to produce analgesia and sedation.","indications":["Acute pain management","Moderate to severe pain"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi4AFBVV95cUxOV2l0elEwbWdKSmtaa0N2OVU3aUJEd2htSGhQb3dWTVh5WHU5WWNUWFhDWlk2YTNYT2N1clFLZlVwdzNKaXJySXRSMVdUZjZKRnpMTzBBMFJIR3V4MG5YcFlESmczN3NoWmQ0S3Y2TExWWjZBaXNHWG5ESmN3Rk9Dc3FkcFBXOWpQNGlTcUxPZjdSN0JRUE90WGtHSlBEUFdDSlpiekc2Wk9oM2pXazVzN3BFYmdqa29DaFpGdVZvQ0ZKTVBTMXBuMDdUQnZyY0xtZlN5SVdHSk03MV84WVZySw?oc=5","date":"2025-09-05","type":"pipeline","source":"PR Newswire","summary":"i-80 Gold Receives Construction Permits and Initiates Underground Development at Archimedes - PR Newswire","headline":"i-80 Gold Receives Construction Permits and Initiates Underground Development at Archimedes","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4AFBVV95cUxQcVJsaDY3emZRbDJ2UFVYY19adzhlQkFscDB6b2ZsdXlCc2hBYVFpU3BtWnc4UVR3cW5ucGNUc3hsYl9WQW9NenRoSDlXSnB1dFJhVmFZZFZXdFRDcklDTkFSMm15VnpuM184Z29iSkRKSjdrMEJoZmZ6bU1KUF8xOS02WVZVdWxGeXRud2dTbUhPNmIxY2JXZzEwUmI5alpLcjg1dnJxd3dQazRoQ3NMTVMyYjloWnRsbUFkM24wejdFOXMzaFdXNXlJdWs1RG9Qb0stYXRVSEVPd09vNVd5Tw?oc=5","date":"2021-05-24","type":"regulatory","source":"BioSpace","summary":"amg International GmbH, a Q3 Medical Devices Ltd Company, Receives European CE Mark Approval for UNITY-B™ Biodegradable Stent - BioSpace","headline":"amg International GmbH, a Q3 Medical Devices Ltd Company, Receives European CE Mark Approval for UNITY-B™ Biodegradable ","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMie0FVX3lxTFBQMUt1dTZUczN0N0JVbUZINjRWRldzeHZ0UGdCdFZjRi1VakY1a0I3a1loQng4cmdUVE55TFMzOFpON2ZXalVkZWF2RGc0VVgzU0gyWUd5ZUhQOE85ODNIQzVUY1RmLWRtM3BWS2ZBSDZDMVozN1pXdzFxWQ?oc=5","date":"2020-02-23","type":"pipeline","source":"ScienceDirect.com","summary":"Nasal drug delivery — Recent developments and future prospects - ScienceDirect.com","headline":"Nasal drug delivery — Recent developments and future prospects","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMie0FVX3lxTE5zRklQaXV5ZmEzOGFxVFpRaTc3QjVYZjZSQVNrQ0ZPbksyOVRIaVdYenY5bjFoYmRBeEFWNUc0QktFLWc3bFdMUlkzdXJhdDVNcW12TVJmRENjRlQ4U2Z2WEZFNU8zRDg5V1JOVS04aXd0SFFsUUt0X0cxbw?oc=5","date":"2020-02-22","type":"pipeline","source":"ScienceDirect.com","summary":"Chitosan in nasal delivery systems for therapeutic drugs - ScienceDirect.com","headline":"Chitosan in nasal delivery systems for therapeutic drugs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigJBVV95cUxQbkNDNEpiWXQ3M2EyY3RVQ0Zrblo4UG8xLWdkQ1NlVnR6Q0FWVkduM2pQVWNqWG9jV1F6R3k1SjRXU2FfekxOaG5faTM1czlFaWRqMUZSWWZGdXMwYTJ1ZlU4UGNHX0xhamFMdElkdTA3SUo3R0t3YllPdHRIcnBPWElpTThyMm1wZHNvaUlFUjEzYU1ELUNSSTJ3V2FRQzJINnhfdlQyTm8xRE5zWmNzbGFfMVhwRENOTUFMUUpxdlRPVE1YWDVYTmxUaUZCUHBVVUVSeFBqaUdORkl5X2w3dldMdmc4ejJHb0NZQzR4ejdnNW9KNV80bmdWYzZodWJUazRaMFpESmZxQQ?oc=5","date":"2019-07-24","type":"pipeline","source":"PR Newswire","summary":"amg International GmbH Announces First Placement of the ARCHIMEDES Biodegradable Biliary and Pancreatic Stent in Hong Kong - PR Newswire","headline":"amg International GmbH Announces First Placement of the ARCHIMEDES Biodegradable Biliary and Pancreatic Stent in Hong Ko","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxOc1loblROeVUwclFUU2o0Zy1lNUIyRl9tNGx5UkRCeDBDZHZhX1VVNTUtdDhRZWRDX1pwS25aWHpPaXRYUll0Q3BXWjFETVI0NGdFdURfZWFuUmdFRnpEVnA5UDFibHQ5N0VlOTF4RmV1VTU1ZFB0bkRQblQ1NTFGVUxDdzZnNVRYaUZETEdTSHAxOTFteEMtdVVUNVJtMVlscmtLWkRWQXVKOGFOMmt3OGIxTUs4a29s?oc=5","date":"2019-03-01","type":"pipeline","source":"BioSpectrum Asia","summary":"Tessa Therapeutics names Jeffrey H. Buchalter to Board of Directors - BioSpectrum Asia","headline":"Tessa Therapeutics names Jeffrey H. Buchalter to Board of Directors","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxOVzU0bmdOWW5ya2lSa0pfbjFFbnhfQmRObjNmVHdNVjg4dlBqWVNJRk5hcFZVWS1tTE5GNkJxNHU1UjVfenVqbVRRWVpkUUlmaHdRdjB5dUkwcWhWSlRMc3dwM1I1cVVZQVNZMzduZkc3Q3lYS2ZOQjk5Mi1fZEFSUURBckljS2pYNDB5WWc4cGtoTE5BcEpkR05fTGNfVFpiYmQ2WUdNM0k?oc=5","date":"2017-07-19","type":"pipeline","source":"BioSpectrum India","summary":"Is Indian pharma ready to tap the European market? - BioSpectrum India","headline":"Is Indian pharma ready to tap the European market?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibEFVX3lxTE42YjFfWGxkb1laSV9lWHhJWlFwMHNzUGVUTFNrd2pVNWJVd2lYQkxCZUZkUHkwWHFKTGg5NTctUld3bTROcF92dWJLRkNvcDkxT1ROODFsUTRCbm1BaFhmX19rRjFsS2JiZzBCQQ?oc=5","date":"2014-07-14","type":"pipeline","source":"Pharmafile","summary":"ProStrakan pays £230m for Archimedes - Pharmafile","headline":"ProStrakan pays £230m for Archimedes","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-gFBVV95cUxQSHhqZE4yMUI1bTFPbk1Ud1QxNWxfM1hTRG5fWFFnUTJvcTk4cU5USTdkTm9TcVlKVmxQbzhzVjFWZEpBMXpvR0F5VjZkY3BMeUFudTVjZWhHaVlhZ0JDUXZsUHNhM0pfTjlOcE5TMWZnSGI2U0kwZkFRTnRvWTdiaEVmWUM5bWg0cmdSM3M3UmRMaWE5ME9VM0hkZVlLQnZhMzBUVHZZTlJzUXRLdkh4THh0WnpqRnFkc21HZmY0b09NdHlKc3ktazlpOTBYZGRiZ0FYNk0xNllOOTFuUXBoazBjUTRUcWlpc0lvOHg2QWh0bHhmbzVVSllR?oc=5","date":"2011-06-30","type":"regulatory","source":"PR Newswire","summary":"FDA Approves Lazanda® - First Fentanyl Nasal Spray - for the Management of Breakthrough Pain in Cancer Patients - PR Newswire","headline":"FDA Approves Lazanda® - First Fentanyl Nasal Spray - for the Management of Breakthrough Pain in Cancer Patients","sentiment":"positive"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}